Obtention and engineering of Non-Human Primate (NHP) antibodies for therapeutics

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 14, 2009, Pages 1633-1638

  Pelat, Thibaut ^a   Hust, Michael ^b   Thullier, Philippe ^a  

^a CENTRE DE RECHERCHES   (France)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Antibody; Humanization; Immune library; Non human primate

Indexed keywords

ANTIGEN; COMPLEMENTARY DNA; FREUND ADJUVANT; IMMUNOGLOBULIN G; OLIGONUCLEOTIDE; RECOMBINANT ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY ISOLATION; BONE MARROW; CLONING; GERM LINE; HEAVY CHAIN; HUMAN; IMMUNIZATION; LIGHT CHAIN; MACACA; NONHUMAN; PHAGE DISPLAY; PLASMA CELL; PRIMATE; REVIEW; RNA EXTRACTION; SEQUENCE ANALYSIS; VDJ EXON;

EID: 77949904546     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709791012283     Document Type: Review

References (24)

1. Thie, H.; Meyer, T.; Schirrmann, T.; Hust, M.; Dubel, S. Phage display derived therapeutic antibodies. Curr. Pharm. Biotechnol., 2008, 9, 439-46.
2. Chassagne, S.; Laffly, E.; Drouet, E.; Herodin, F.; Lefranc, M. P.; Thullier, P. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol. Immunol., 2004, 41, 539-46.
3. Pelat, T.; Hust, M.; Laffly, E.; Condemine, F.; Bottex, C.; Vidal, D.; Lefranc, M. P.; Dubel, S.; Thullier, P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob. Agents Chemother., 2007, 51, 2758-64.
4. Pelat, T.; Hust, M.; Hale, M.; Lefranc, M. P.; Dubel, S.; Thullier, P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol., 2009, 9, 60.
5. Laffly, E.; Danjou, L.; Condemine, F.; Vidal, D.; Drouet, E.; Lefranc, M. P.; Bottex, C.; Thullier, P. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob. Agents Chemother., 2005, 49, 3414-20.
6. Schütte, M.; Pelat, T.; Wezler, X.; Rosenstock, P.; Hinz, D.; Kirsch, M.; Schirrmann, T.; Thullier, P.; Hust, M.; Dübel, S. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS ONE, 2009, 4(8), e6625.
7. Pelat, T.; Bedouelle, H.; Rees, A. R.; Crennell, S. J.; Lefranc, M. P.; Thullier, P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J. Mol. Biol., 2008, 384, 1400-7.
8. Pelat, T.; Thullier, P. Non-human primate immune libraries combined with germline humanization : an (almost) new, and powerful approach for the isolation of therapeutic antibodies. MAbs, 2009, 1, 377-381
9. Newman, R. A.; N. Hanna, N.; Raab, R. W. European patent 1, 266,965 B1, 24 June 1992.
10. Wild, M. A.; Xin, H.; Maruyama, T.; Nolan, M. J.; Calveley, P. M.; Malone, J. D.; Wallace, M. R.; Bowdish, K. S. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol., 2003, 21, 1305-6.
11. Barbas, C. F. Phage display : a laboratory manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2001.
12. Stittelaar, K. J.; Neyts, J.; Naesens, L.; van Amerongen, G.; van Lavieren, R. F.; Holy, A.; De Clercq, E.; Niesters, H. G.; Fries, E.; Maas, C.; Mulder, P. G.; van der Zeijst, B. A.; Osterhaus, A. D. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature, 2006, 439, 745-748.
13. Murphy, K. P.; Travers, P.; Walport, M.; Janeway, C. Janeway's immunobiology; 7th ed.; Garland Science: New York, 2008.
14. Hoogenboom, H. R.; Winter, G. By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol., 1992, 227, 381-8.
15. Glamann, J.; Burton, D. R.; Parren, P. W.; Ditzel, H. J.; Kent, K. A.; Arnold, C.; Montefiori, D.; Hirsch, V. M. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-termnonprogressor SIV-infected macaque. J. Virol., 1998, 72, 585-92.
16. Pelat, T.; Hust, M.; Hale, M.; Lefranc, M. P.; Dübel, S.; Thullier, P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. Manuscript in Progress, 2009.
17. Hust, M.; Dubel, S.; Schirrmann, T. Selection of recombinant antibodies from antibody gene libraries. Methods Mol. Biol., 2007, 408, 243-55.
18. Kirsch, M. I.; Hulseweh, B.; Nacke, C.; Rulker, T.; Schirrmann, T.; Marschall, H. J.; Hust, M.; Dubel, S. Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol., 2008, 8, 66.
19. Rondot, S.; Koch, J.; Breitling, F.; Dubel, S. A helper phage to improve single-chain antibody presentation in phage display. Nat Biotechnol., 2001, 19, 75-8.
20. Soltes, G.; Hust, M.; Ng, K. K.; Bansal, A.; Field, J.; Stewart, D. I.; Dubel, S.; Cha, S.; Wiersma, E. J. On the influence of vector design on antibody phage display. J. Biotechnol., 2007, 127, 626-37.
21. Laffly, E.; Pelat, T.; Cedrone, F.; Blesa, S.; Bedouelle, H.; Thullier, P. Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J. Mol. Biol., 2008, 378, 1094-103.
22. Harris, W. J.; Adair, J. R. In Antibody Therapeutics; CRC Press: Boca Raton, Fla., 1997, p. 85-110.
23. Foote, J.; Winter, G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol., 1992, 224, 487-99.
24. Tan, P.; Mitchell, D. A.; Buss, T. N.; Holmes, M. A.; Anasetti, C.; Foote, J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol., 2002, 169, 1119-25.